Skip to Content
Mentor: Raymond Hohl, MD, PhD
Year Entered Into Program: 2011
PhD Institution: University of Iowa, 2014
is the most common cancer of males in the United States and the second most
deadly cancer. Of the prostate cancer deaths, more than 80% will have skeletal
metastasis, making novel cancer treatments and adjunct therapies targeting
metastasis vital in decreasing death rates. One proposed scheme of cancer
metastasis utilizes previous work establishing the general importance and
sufficiency of the Rho family in altering proteins involved in cell survival,
cell cycle and the proteolysis step of invasion. While a majority of the work
has focused on Rho family mRNA and selective cancers, protein activity at
various stages of cancer metastasis and inhibition of specific Rho proteins have
not been explored. Utilizing nitrogenous bisphosphonates as inhibitors upstream
of the Rho GTPase family both in vivo and in vitro, we hope to
elucidate the mechanism by which the modified Rho subfamily of proteins are able
to promote tumorigenesis, in addition to testing various bisphosphonates as
novel prostate cancer adjunct therapies.
Fletcher, J.T. and Reilly,
J.E.: Fast dye salts provide fast access to azidoarene synthons in
multi-step one-pot tandem click transformations. Tetrahedron Lett.
52(42):5512-5515, 2011. PMCID: PMC3285242
Copyright © 2011 The University of Iowa. All Rights Reserved.